- Galleri multi-cancer signal blood test
- Recognized multi-cancer detection brand in practice today
- Active population screening programs in practice today
- No fasting required before blood collection
- Study-reported false-positive rate of 0.4%
GRAIL
Multi-cancer early detection from blood
SF7.98
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Surface biomarker signals across data
Surface biomarker signals across data
Best for
Health systems and population screening programs
Pricing
Custom
Free plan
Check vendor
SoftFinders Score
7.98 / 10
Overview
What is GRAIL?
GRAIL is a multi-cancer early detection company using AI to analyze cell-free DNA signals through the Galleri blood test for health systems and screening programs.
- Clinical role: It supports genomic interpretation rather than standalone results, so clinical context remains essential for every care decision informed by its findings.
- Best-fit environment: Health systems and screening programs benefit most when they have defined pathways for test delivery, interpretation, referral, and follow-up.
- Evaluation priorities: Buyers should assess the test menu, turnaround time, EHR delivery, interpretation support, and fit across oncology and precision-medicine services.
- Commercial model: Pricing is sales-led and scoped per buyer, while coverage and reimbursement continue to evolve.
GRAIL is best assessed as a population-level screening option whose value depends on clinical pathways, implementation readiness, and local access conditions.
KEY FEATURES
What you get out of the box
Cancer Detection
Supports early cancer detection workflows
Biomarker Discovery
Surfaces biomarker signals across data
Clinical Trials
Connects insights with clinical trial options
Precision Care
Supports precision-care decisions across patients
Data Platform
Provides a unified clinico-molecular data platform
Reporting Tools
Reports genomic findings for care teams
USE CASES
Where teams put it to work
Surface biomarker signals across data
Connect genomic insights with care decisions
Support precision oncology workflows
Bridge genomic data and clinical trials
Interpret genomic test results in context
Support early cancer detection programs
Offer eligible employees cancer screening benefits
Editorial Take
What we like, and what to verify
- Coverage and reimbursement continue to evolve
- Clinical guidelines for use remain in development
- Programs require population-level commitment for now
- Not yet approved by the US FDA
- False-positive and false-negative results remain possible
- Positive results require confirmatory diagnostic testing
- Most US insurance plans exclude coverage
- NHS-Galleri trial missed its primary endpoint
Screenshots
A look inside
GRAIL homepage screenshotAlternatives
Tools to consider next
Tempus SF 8.3
Why consider it
Precision medicine platform across data and AI
Freenome SF 7.88
Why consider it
Multiomic AI for early cancer detection
Abridge SF 8.78
Why consider it
Generative AI scribe for health systems
Nuance DAX Copilot SF 8.7
Why consider it
Microsoft and Nuance enterprise ambient scribe
Suki AI SF 8.4
Why consider it
Voice-driven AI scribe and EHR assistant
Nabla Copilot SF 8.4
Why consider it
Ambient AI scribe for independent clinicians
USER REVIEWS
GRAIL Reviews
Published user reviews are moderated and kept separate from the SoftFinders Score.
No published reviews yet.
Reviews from real users will appear here once published.
Used GRAIL?
Share your experience with other buyers.
FAQ